NEW YORK – Mount Sinai researchers are receiving a 300-year grant from the National Institutes of Health to develop and study an AI-powered model to identify the risk of cardiovascular disease events in patients with obstructive sleep apnea. Received a $1 million grant. Researchers used machine learning techniques on a comprehensive multimodal dataset to identify patients at increased risk of fat and cholesterol buildup in artery walls and risk of cardiovascular events such as heart attack and stroke. We plan to identify patients with increased The researchers found that this approach also predicted the cardiovascular therapeutic efficacy of CPAP therapy for OSA patients who scored as “not sleepy” on standard clinical tests, indicating that these patients benefit most from the use of CPAP. It said it could help identify patients who should be avoided. The study was based on the team’s recently published study that revealed the potential harms of CPAP therapy for insomnia patients with OSA and acute coronary syndromes. These findings highlighted the importance of identifying her OSA patients who may benefit from CPAP and guiding the team toward a more individualized treatment strategy. “We are inspired by the transformative potential of machine learning technology in healthcare, especially in analyzing vast amounts of complex data to personalize treatment strategies,” said Girish Nadkarni, Ph.D., MPH. said Dr. Arthur M. Fishberg, Irene Professor of Medicine. Director of the Charles Bronfman Institute for Personalized Medicine and System Lead for Data-Driven and Digital Health at Icahn Mount Sinai. “Our research aims to optimize treatment plans, improve patient outcomes, and reduce the burden on individuals and healthcare systems from cardiovascular disease events associated with sleep apnea by providing decision support tools. , has the potential to revolutionize the management of obstructive sleep apnea.” The researchers plan to use data from two cohorts. One is the Multi-Ethnic Atherosclerosis Study (MESA) cohort of over 6,000 ethnically diverse, generally healthy, non-sleepy participants, and the other is a sleep apnea study of over 2,500 participants. Vascular Endpoints (SAVE) randomized clinical trial. Non-drowsy participants with moderate to severe obstructive sleep apnea and cardiovascular disease. They used these datasets to identify key variables that predict atherosclerosis progression and cardiovascular events, and to identify subgroups with differential treatment effects with CPAP on events based on demographic and risk characteristics. identify and validate the model within the Mount Sinai Health System. Uses clinical data from electronic medical records.